Skip to main content
SpringerLink
Log in

Médicaments de l’ostéolyse tumorale

  • Synthèse / Review Article
  • Published:
Oncologie

Abstract

Malignant tumour osteolysis is a frequent complication of cancers and multiple myeloma. It can cause skeletal related-events including pathological fractures, spinal cord compression, bone pain or hypercalcemia, with a significant alteration of quality of life and survival. Bisphosphonates (BP) play an important role in the management of this malignant osteolysis, via an inhibition of osteoclastmediated bone resorption, and a potential direct anti-tumour activity. Novel therapeutic targets such as specific RANKL antibodies are being investigated currently and are promising.

Résumé

L’ostéolyse tumorale maligne est une complication fréquente de nombreux cancers et du myélome multiple. Elle peut être à l’origine d’événements osseux tels que fractures pathologiques, compression médullaire, douleurs osseuses ou hypercalcémie maligne, affectant la qualitéde vie et la survie. Les bisphosphonates (BP) ont un rôle important dans le traitement de cette ostéolyse maligne en bloquant l’activité ostéoclastique et peut-être également en raison d’une action antitumorale directe. De nouvelles molécules ayant des propriétés antirésorptives telles que les anticorps anti-RANKL s’avè rent également prometteuses.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Références

  1. Aapro M, Abrahamsson PA, Body JJ, et al. (2008) Guidance on the use of bisphosphonates in solid tumors: recommendations of an international expert panel. Ann Oncol 19: 420–432

    Article  PubMed  CAS  Google Scholar 

  2. Afssaps, 18 décembre 2007 Recommandations sur la prise en charge buccodentaire des patients traités par bisphosphonates. www.afssaps.sante.fr

  3. Berenson JR, Lichtenstein A, Porter L, et al. (1998) Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 16: 593–602

    PubMed  CAS  Google Scholar 

  4. Berenson JR, Rosen LS, Howell A, et al. (2001) Zoledronic acid reduces skeletalrelated events in patients with osteolytic metastases. Cancer 91: 1191–1200

    Article  PubMed  CAS  Google Scholar 

  5. Body JJ, Diel IJ, Lichinitser MR, et al. (2003) Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14: 1399–1405

    Article  PubMed  Google Scholar 

  6. Body JJ, Diel IJ, Lichinitzer M, et al. (2004) Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 90: 1133–1137

    Article  PubMed  CAS  Google Scholar 

  7. Dimipoulos MA, Kastritis E, Bamia C, et al. (2008) Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol [Epub ahead of print]

  8. Djulbegovic B, Wheatley K, Ross J, et al. (2002) Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev: CD003188

  9. Ha TC, Li H (2007) Meta-analysis of clodronate and breast cancer survival. Br J Cancer 96: 1796–1801

    Article  PubMed  CAS  Google Scholar 

  10. Heidenreich A, Elert A, Hofmann R (2002) Ibandronate in the treatment of prostate cancer associated painful osseous metastases. Prostate Cancer Prostatic Dis 5: 231–235

    Article  PubMed  CAS  Google Scholar 

  11. Hillner BE, Ingle JN, Chlebowski RT, et al. (2003) American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21: 4142–4157

    Google Scholar 

  12. Khosla S, Burr D, Cauley J, et al. (2007) Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22: 1479–1491

    Article  PubMed  Google Scholar 

  13. Kohno N, Aogi K, Minami H, et al. (2005) Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomised, placebo-controlled trial. J Clin Oncol 23: 1–8

    Article  CAS  Google Scholar 

  14. Kristensen B, Ejlertsen B, Groenvold M, et al. (1999) Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med 246: 67–74

    Article  PubMed  CAS  Google Scholar 

  15. Kyle RA, Yee GC, Somerfield MR, et al. (2007) American Society of Clinical Oncology 2007. Clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 25: 1–9

    Article  CAS  Google Scholar 

  16. Lahtinen R, Laasko M, Pavla I, et al. (1992) Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 340: 1049–1052

    Article  PubMed  CAS  Google Scholar 

  17. Lipton A, Cook R, Saad F, et al. (2008) Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 113: 193–201

    Article  PubMed  CAS  Google Scholar 

  18. Lipton A, Steger GG, Figueroa J, et al. (2007) Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 25: 4431–4437

    Article  PubMed  CAS  Google Scholar 

  19. Lipton A, Theriault RL, Hortobagyi GN, et al. (2000) Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. Long-term follow-up of two randomised, placebo-controlled trials. Cancer 88: 1082–1090

    Article  PubMed  CAS  Google Scholar 

  20. Major P, Lortholary A, Hon J, et al. (2001) Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomised, controlled clinical trials. J Clin Oncol 19: 558–567

    PubMed  CAS  Google Scholar 

  21. Mason MD, Sydes MR, Glaholm J, et al. (2007) Oral sodium clodronate for nonmetastatic prostate cancer results of a randomised double-blind placebo-controlled trial: medical research council PR04 (ISRCTN61384873). J Natl Cancer Inst 99: 765–776

    Article  PubMed  CAS  Google Scholar 

  22. McCloskey EV, Dunn JA, Kanis JA, et al. (2001) Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br J Haematol 113: 1035–1043

    Article  PubMed  CAS  Google Scholar 

  23. Menssen HD, Sakalova A, Fontana A, et al. (2002) Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol 20: 2353–2359

    Article  PubMed  CAS  Google Scholar 

  24. Mystakidou K, Katsouda E, Parpa E, et al. (2005) Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. Med Oncol 22: 195–201

    Article  PubMed  CAS  Google Scholar 

  25. Oyajobi BO, Franchin G, Williams PJ, et al. (2003) Dual effects of macrophage inflammatory protein-1 alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood 102: 311–319

    Article  PubMed  CAS  Google Scholar 

  26. Paterson AH, Powles TJ, Kanis JA, et al. (1993) Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11: 59–65

    PubMed  CAS  Google Scholar 

  27. Pavlakis N, Schmidt RL, Stockler M (2005) Bisphosphonates for breast cancer. Cochrane Database Syst Rev: CD003474

  28. Purohit OP, Radstone CR, Anthony C, et al. (1995) A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcemia of malignancy. Br J Cancer 72: 1289–1293

    PubMed  CAS  Google Scholar 

  29. Ripamonti CI, Maniezzo M, Campa T, et al. (2008) Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumor patients with bone metastasis treated with bisphosphonates. Ann Oncol [Epub ahead of print]

  30. Roodman GD (2004). Mechanisms of bone metastasis. New Engl J Med 350: 1655–1664

    Article  PubMed  CAS  Google Scholar 

  31. Rosen LS, Gordon D, Dugan W Jr, et al. (2004) Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 100: 36–43

    Article  PubMed  CAS  Google Scholar 

  32. Rosen LS, Gordon D, Kaminski M, et al. (2003) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. A randomised, double-blind, multicenter, comparative trial. Cancer 98: 1735–1744

    Article  PubMed  CAS  Google Scholar 

  33. Rosen LS, Gordon D, Tchelmedyian S, et al. (2004) Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non-small cell lung carcinoma and other solid tumors. A randomized, phase III, double-blind, placebo-controlled trial. Cancer 100: 2613–2621

    Article  PubMed  CAS  Google Scholar 

  34. Saad F, Gleason DM, Murray R, et al. (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96: 879–882

    Article  PubMed  CAS  Google Scholar 

  35. Small EJ, Smith MR, Seaman JJ, et al. (2003) Combined analysis of two multicenter, randomised, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 21: 4277–4284

    Article  PubMed  CAS  Google Scholar 

  36. Stresing V, Daubiné F, Benzaid I, et al. (2007) Bisphosphonates in cancer therapy. Cancer Lett 257: 16–35

    Article  PubMed  CAS  Google Scholar 

  37. Tubiana-Hulin M, Beuzeboc P, Mauriac L, et al. (2001) Essai comparatif randomiséen double insu: clodronate oral 1 600 mg/j versus placebo chez des patients avec métastases osseuses de cancer du sein. Bull Cancer 88: 701–707

    PubMed  CAS  Google Scholar 

  38. Winter MC, Holen I, Coleman RE (2008) Exploring the antitumor activity of bisphosphonates in early breast cancer. Cancer Treat Rev 34: 453–475

    Article  PubMed  CAS  Google Scholar 

  39. Yuen KK, Shelley M, Sze WM, et al. (2006) Bisphosphonates for advanced prostate cancer. Cochrane Database Syst Rev: CD006250

Download references

Author information

Authors and Affiliations

  1. Service de rhumatologie, CHU de Poitiers, universitéde Poitiers, 2, rue de la Milétrie, F-86021, Poitiers, France

    F. Debiais & C. Martin

Authors
  1. F. Debiais
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F. Debiais.

About this article

Cite this article

Debiais, F., Martin, C. Médicaments de l’ostéolyse tumorale. Oncologie 11, 16–21 (2009). https://doi.org/10.1007/s10269-008-0992-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10269-008-0992-2

Keywords

Mots clés

Search

Navigation